Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Expansive, Diverse and Compelling New Cancer Research at the 2022 ASCO Annual Meeting
Read press release here
(**All times noted are Eastern Standard Time)
Friday, June 3, 2022
| 3:00pm |
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1 Author: Andrew M. Evens, DO, MSc |
| 3:45pm |
Germline Epigenetic Modification and Cancer Risk Discussant: Shridar Ganesan, MD, PhD
Genitourinary Cancer—Kidney and Bladder Panel Chair: Eric A. Singer, MD, MA, MS, FACS, FASCO
|
Saturday, June 4, 2022
| 9:00am |
A Urology Perspective Chair: Saum Ghodoussipour, MD
|
| 2:15pm |
A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL- 0255, in adults with advanced malignancies Lead Author: Eugenia Girda, MD, FACOG
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors Lead Author: Sanjay Goel, MD, MS
Gaps in adolescent and young adult oncology education during medical and pediatric hematology/oncology fellowship training Author: Scott Moerdler, MD
Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma Lead Author: Karan Pandya, MD |
| 4:00pm |
Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 3-year follow-up from the FD cohort of the phase 2 CAPTIVATE study Author: Rajat Bannerji, MD, PhD |
| 5:30pm |
Impact of social media on the emotional health and burnout of pediatric and adult oncology professionals: A SWOG and COG survey Lead Author: Scott Moerdler, MD |
Sunday, June 5, 2022
| 5:30pm |
Palliative Care Perspective Chair: Biren Saraiya, MD |
Monday, June 6, 2022
| 9:00am |
Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867 Lead Author: Salma Jabbour, MD
Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma Lead Author: Scott Moerdler, MD |
| 2:15pm |
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials Lead Author: Matthew Pierre Deek, MD |
| 4:00pm |
Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study Author: Teena Bhatla, MD |